Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin
- PMID: 750112
- DOI: 10.1007/BF00257158
Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin
Abstract
Previous studies on structure-activity relationships of anthracycline antitumor antibiotics have shown that removal of the methoxyl group at position 4 of the aglycone causes a marked increase in the potency of the compounds: 4-demethoxydaunorubicin and 4-demethoxyadriamycin had an antitumor effect similar to that of the parent compound at doses five to eight times lower, and they were active even when administered orally. This paper reports the effects of further substitutions at positions 1, 2, 3, and 4 of 4-demethoxy aglycone. The introduction of methyl groups at positions 2 and 3, or 1 and 4 resulted in decreased cytotoxicity and biological activity. The addition of a benzoyl ring at positions 2 and 3 decreased the activity further. 1,4-Dichloro-4-demethoxydaunorubicin and 2,3-dichloro-4-demethoxydaunorubicin were respectively as active and 2.5 times less active than was daunorubicin against HeLa cells in vitro while they were inactive against P388 and L1210 leukemias in vivo. 2,3-Dimethyl-4-demethoxyadriamycin showed an antitumor activity against mouse leukemias that was slightly higher than was that of adriamycin.
Similar articles
-
Antileukemic activity of 4-demethoxydaunorubicin in mice.Tumori. 1980 Oct 31;66(5):549-64. doi: 10.1177/030089168006600503. Tumori. 1980. PMID: 6936969
-
Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.Cancer Res. 1977 Dec;37(12):4523-8. Cancer Res. 1977. PMID: 922737
-
Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.Cancer Treat Rep. 1978 Mar;62(3):375-80. Cancer Treat Rep. 1978. PMID: 647696
-
Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.Cancer Treat Rev. 1987 Dec;14(3-4):319-27. doi: 10.1016/0305-7372(87)90024-7. Cancer Treat Rev. 1987. PMID: 3326668 Review. No abstract available.
-
Towards selectivity? Approaches to the design of new anti-tumour agents--II.Cancer Treat Rev. 1977 Jun;4(2):119-34. doi: 10.1016/s0305-7372(77)80009-1. Cancer Treat Rev. 1977. PMID: 408006 Review. No abstract available.
Cited by
-
Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.Cancer Chemother Pharmacol. 1983;10(2):84-9. doi: 10.1007/BF00446215. Cancer Chemother Pharmacol. 1983. PMID: 6831630
-
Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.Cancer Chemother Pharmacol. 1979;3(4):261-9. doi: 10.1007/BF00254742. Cancer Chemother Pharmacol. 1979. PMID: 294954
-
Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.Br J Cancer. 1984 Jul;50(1):91-6. doi: 10.1038/bjc.1984.143. Br J Cancer. 1984. PMID: 6378238 Free PMC article.
-
Evaluation of new anthracycline analogs with the human tumor stem cell assay.Cancer Chemother Pharmacol. 1981;6(2):103-9. doi: 10.1007/BF00262325. Cancer Chemother Pharmacol. 1981. PMID: 6946877
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources